XML 9 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover Page - USD ($)
$ in Billions
 12 Months Ended
Sep. 30, 2024
Nov. 20, 2024
Mar. 31, 2024
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Sep. 30, 2024    
Current Fiscal Year End Date --09-30    
Document Transition Report false    
Entity File Number 001-38042    
Entity Registrant Name ARROWHEAD PHARMACEUTICALS, INC.    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 46-0408024    
City Area Code 626    
Local Phone Number 304-3400    
Entity Address, Address Line One 177 E. Colorado Blvd    
Entity Address, Address Line Two Suite 700    
Entity Address, City or Town Pasadena    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91105    
Security12b Title Common Stock, $0.001 par value    
Trading Symbol ARWR    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Document Financial Statement Error Correction [Flag] false    
Entity Public Float     $ 3.0
Entity Common Stock Shares Outstanding   124,434,442  
Documents Incorporated by Reference
None.
    
Amendment Description Arrowhead Pharmaceuticals, Inc. (the “Company” or “Arrowhead”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to its Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024 (the “Original Report”) solely to include the information required by Items 10 through 14 of Part III of Form 10-K (the “Part III Information”) not included in the Original Report in order to comply with General Instruction G.3 of Form 10-K. The Company’s Definitive Proxy Statement on Schedule 14A containing the Part III Information was filed with the SEC on January 29, 2025 (the “Proxy Statement”) was filed three minutes after the filing deadline on the 120th day after the Company’s fiscal year end. Except as noted below, the Part III Information included in this Amendment is as of January 28, 2025.Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed herewith. Because no financial statements have been included in this Amendment, and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.Except as described above, no other changes have been made to the Original Report and this Amendment does not modify, amend or update in any way any of the financial or other information contained in the Original Report or the Proxy Statement. This Amendment does not reflect events that may have occurred subsequent to the date of filing of the Original Report or the Proxy Statement. Accordingly, this Amendment should be read in conjunction with the Original Report and the Proxy Statement.    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000879407    
Amendment Flag true